Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1576 - 1600 of 2160 in total
First-in-class potent and selective inhibitor of the BRD4 signaling pathway.
Investigational
Matched Iupac: … chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9- …
Experimental
Matched Iupac: … 7-ethoxy-9-imino-9,10-dihydroacridin-3-amine …
Matched Salts cas: … 6402-23-9
Investigational
Ziltivekimab is under investigation in clinical trial NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation).
Investigational
Investigational
Matched Iupac: … 2-{4-[(9R)-9-hydroxy-2-(3-hydroxy-3-methylbutoxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl …
Experimental
Matched Iupac: … -9-ylium ... (6S)-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-hydroxy-6,7-dihydro-3H-9lambda5-purin …
Investigational
Experimental
Matched Iupac: … 2,8,16,17,19,20-hexaazatetracyclo[12.5.2.1^{3,7}.0^{17,21}]docosa-1(20),3(22),4,6,14(21),15,18-heptaen-9- …
Cannabinol (CBN) is a physiologically inactive constituent of Cannabis sativa.
Experimental
Investigational
Experimental
Investigational
Matched Iupac: … [3-(10,10-dimethyl-9,10-dihydroanthracen-9-ylidene)propyl]dimethylamine …
Experimental
Matched Iupac: … 2-(9-oxo-9,10-dihydroacridin-10-yl)acetic acid …
Experimental
Matched Iupac: … ),9-pentaen-3-one ... 7-[(2-aminoethyl)amino]-9-fluoro-5-(1H-pyrrol-2-yl)-2-azatricyclo[6.3.1.0^{4,12}]dodeca-1(11),4,6,8(12 …
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of intestinal-homing lymphocytes.[A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some...
Investigational
CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.
Investigational
CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
Investigational
Investigational
Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Investigational
Withdrawn
Experimental
Matched Iupac: … -purin-9-ylium ... 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methyl-6-oxo-6,7-dihydro-3H-9lambda5 …
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Investigational
Displaying drugs 1576 - 1600 of 2160 in total